Newborn screening platform for lysosomal storage disorders with FDA clearance and CE mark.

SEEKER is a high throughput laboratory solution that quantitatively measures the activity of lysosomal enzymes from newborn dried blood spot specimens. Reduced activity of these enzymes may be indicative of Mucopolysaccharidosis Type I (MPS I), Pompe, Gaucher or Fabry disease.

Everything your lab needs for LSD screening in one small workstation.

False Positive Rates: SEEKER vs. NeoLSD

SEEKER was the first FDA-cleared product for newborn screening of lysosomal storage disorders (LSDs) in February 2017. Now that a second product NeoLSD has received clearance, a true clinical data comparison can be made from the 510(k) submissions. The results? NeoLSD’s false positive rates are roughly double those of SEEKER.

SEEKER Brochure


Workflow in Action


“FDA clearance enables state laboratories to confidently implement testing while minimizing the validation effort resulting in a cost effective implementation.”